Therapeutic Area

COVID-19

Therapeutic area intelligence for COVID-19 with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 2

Companies

GSK →

Moderna →

Assets

Analysis →

COVAC-2 →

COVID-19 →

Recent signals(4)

StrategyJune 20, 2026

Analysis of Oral Nirmatrelvir/Ritonavir Utilization in Spain for COVID-19

The analysis highlights the potential benefits of increasing oral nirmatrelvir/ritonavir use in outpatient settings for high-risk COVID-19 patients in Spain.

ClinicalJune 17, 2026

OTAC Trial Evaluates Anti-COVID-19 Immunoglobulin in Outpatients

The OTAC trial is assessing the safety and efficacy of hIVIG versus placebo in outpatients with COVID-19.

ClinicalJune 16, 2026

NextCOVE trial shows mRNA-1283 vaccine elicits higher nAb responses than mRNA-1273

The mRNA-1283 vaccine met non-inferiority criteria against mRNA-1273 and elicited higher neutralizing antibody responses.

StrategyJune 13, 2026

COVAC-2 Vaccine Shows Safety and Immunogenicity as COVID-19 Booster in Phase 1 Trial

COVAC-2, a recombinant protein vaccine, demonstrated a favorable safety profile and strong immune responses as a booster in previously vaccinated adults.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

COVID-19 →

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.